Use of medications during pregnancy and breastfeeding for Crohn’s disease and ulcerative colitis

References

• Chouraki V, Savoye G, Dauchet L, et al. The changing pattern of Crohn’s disease incidence in northern France: a continuing increase in the 10- to 19-year-old age bracket (1988-2007). Aliment Pharmacol Ther. 2011;33:1133–1142.
   PubMed Web of Science ®Google Scholar
• Gallinger ZR, Rumman A, Nguyen GC. Perceptions and attitudes towards medication adherence during pregnancy in inflammatory bowel disease. J Crohns Colitis. 2016;10:892–897.
   PubMed Web of Science ®Google Scholar
• Kane S, Lemieux N. The role of breastfeeding in postpartum disease activity in women with inflammatory bowel disease. Am J Gastroenterol. 2005;100:102–105.
   PubMed Web of Science ®Google Scholar
• Lee S, Seow CH, Adhikari K, et al. Pregnant women with IBD are more likely to be adherent to biologic therapies than other medications. Aliment Pharmacol Ther. 2020;51:544–552.
   PubMed Web of Science ®Google Scholar
• Matro R, Martin CF, Wolf D, et al. Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel diseases and effects of breastfeeding on infections and development. Gastroenterology. 2018;155:696–704.
   PubMed Web of Science ®Google Scholar
• Nielsen MJ, Norgaard M, Holland-Fisher P, et al. Self-reported antenatal adherence to medical treatment among pregnant women with Crohn’s disease. Aliment Pharmacol Ther. 2010;32:49–58.
   PubMed Web of Science ®Google Scholar
• Selinger CP, Eaden J, Jones DB, et al. Modifiable factors associated with nonadherence to maintenance medication for inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:2199–2206.
   PubMed Web of Science ®Google Scholar
• Bush MC, Patel S, Lapinski RH, et al. Perinatal outcomes in inflammatory bowel disease. J Matern Fetal Neonatal Med. 2004;15:237–241.
   PubMedGoogle Scholar
• Hudson M, Flett G, Sinclair T, et al. Fertility and preganncy in inflammatory bowel disease. Int J Gynaecol Obstet. 1997;58:229–237.
   PubMed Web of Science ®Google Scholar
• Kammerlander H, Nielsen J, Kjeldsen J, et al. The effect of disease activity on birth outcomes in a nationwide cohort of women with moderate to severe inflammatory bowel disease. Inflamm Bowel Dis. 2017;23:1011–1018.
   PubMed Web of Science ®Google Scholar
• Khosla R, Willoughby C, Jewell D. Crohn’s disease and pregnancy. Gut. 1984;25:52–56.
   PubMed Web of Science ®Google Scholar
• Lee HH, Bae JM, Lee BI, et al. Pregnancy outcomes in women with inflammatory bowel disease: a 10-year nationwide population-based cohort study. Aliment Pharmacol Ther. 2020;51:861–869.
   PubMed Web of Science ®Google Scholar
• Morales M, Berney T, Jenny A, et al. Crohn’s disease as a risk factor for the outcome of pregnancy. Hepato-Gastroenterol. 2000;47:1595–1598.
   PubMedGoogle Scholar
• Nielsen OH, Andreasson B, Bondesen S, et al. Pregnancy in ulcerative colitis. Scand J Gastroenterol. 1983;18:735–742.
   PubMed Web of Science ®Google Scholar
• Norgard B, Hundborg HH, Jacobsen BA, et al. Disease activity in pregnant women with Crohn’s disease and birth outcomes: a regional Danish cohort study. Am J Gastroenterol. 2007;102:1947–1954.
   PubMed Web of Science ®Google Scholar
• Reddy D, Murphy SJ, Kane SV, et al. Relapses of inflammatory bowel disease during pregnancy: in-hospital management and birth outcomes. Am J Gastroenterol. 2008;103:1203–1209.
   PubMed Web of Science ®Google Scholar
• Stephansson O, Larsson H, Pedersen L, et al. Congenital abnormalities and other birth outcomes in children born to women with ulcerative colitis in Denmark and Sweden. Inflamm Bowel Dis. 2011;17:795–801.
   PubMed Web of Science ®Google Scholar
• Francine R, Pascale S, Aline H. Congenital anomalies: prevalence and risk factors. Univers J Public Health. 2014;2:58–63.
   Google Scholar
• Magnus MC, Wilcox AJ, Morken NH, et al. Role of maternal age and pregnancy history in risk of miscarriage: prospective register based study. BMJ. 2019;364:869.
   PubMed Web of Science ®Google Scholar
• Jarnerot G, Into-Malmberg MB, Esbjorner E. Placental transfer of sulphasalazine and sulphapyridine and some of its metabolites. Scand J Gastroenterol. 1981;16:693–697.
   PubMed Web of Science ®Google Scholar
• Myers B, Evans D, Rhodes J, et al. Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut. 1987;28:196–200.
   PubMed Web of Science ®Google Scholar
• Ban L, Tata LJ, Fiaschi L, et al. Limited risks of major congenital anomalies in children of mothers with IBD and effects of medications. Gastroenterology. 2014;146:76–84.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Sandborn WJ, Li DK, et al. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology. 2007;133:1106–1112.
   PubMed Web of Science ®Google Scholar
• Molnar T, Farkas K, Nagy F, et al. Pregnancy outcome in patients with inflammatory bowel disease according to the activity of the disease and the medical treatment: a case-control study. Scand J Gastroenterol. 2010;45:1302–1306.
   PubMed Web of Science ®Google Scholar
• Rahimi R, Nikfar S, Rezaie A, et al. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. Reprod Toxicol. 2008;25:271–275.
   PubMed Web of Science ®Google Scholar
• Colombel J, Brabant G, Gubler M, et al. Renal insufficiency in infant: side-effect of prenatal exposure to mesalazine? Lancet. 1994;644:620–621.
   Google Scholar
• Marteau P, Devaux C. Mesalazine during pregnancy. Lancet. 1994;344:1708–1709.
   PubMed Web of Science ®Google Scholar
• Diav-Citrin O, Park Y, Veerasuntharam G, et al. The safety of mesalamine in human pregnancy: a prospective controlled cohort study. Gastroenterol. 1998;114:23–28.
   PubMed Web of Science ®Google Scholar
• Norgard B, Fonager K, Pedersen L, et al. Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy: a Danish cohort study. Gut. 2003;52:243–247.
   PubMed Web of Science ®Google Scholar
• Marteau P, Tennenbaum R, Elefant E, et al. Foetal outcome in women with inflammatory bowel disease treated during pregnancy with oral mesalazine microgranules. Aliment Pharmacol Ther. 1998;12:1101–1108.
   PubMed Web of Science ®Google Scholar
• Hernandez-Diaz S, Mitchell AA, Kelley KE, et al. Medications as a potential source of exposure to phthalates in the U.S. population. Environ Health Perspect. 2009;117:185–189.
   PubMed Web of Science ®Google Scholar
• Jurewicz J, Hanke W. Exposure to phthalates: reproductive outcome and children health. A review of epidemiological studies. Int J Occup Med Environ Health. 2011;24:115–141.
   PubMed Web of Science ®Google Scholar
• Singh A, Martin CF, Kane SV, et al. Is asacol use associated with congenital anomalies? Results from a nationwide prospective pregnancy registry: su1030. Gastroenterology. 2013 144 DOI:10.1053/j.gastro.2012.10.005
   PubMedGoogle Scholar
• Nguyen GC, Seow CH, Maxwell C, et al. The toronto consensus statements for the management of inflammatory bowel disease in pregnancy. Gastroenterology. 2016;150:734–57 e1.
   PubMed Web of Science ®Google Scholar
• Baggott J, Morgan S, Ha T, et al. Inhibition of folate-dependent enzymes by non-steroidal anti-inflammatory drugs. Biochem J. 1992;282:197–202.
   PubMed Web of Science ®Google Scholar
• Mogadam M, Dobbins W, Korelitz B, et al. Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterol. 1981;80:385–386.
   Web of Science ®Google Scholar
• Willoughby C, Truelove S. Ulcerative colitis and pregnancy. Gut. 1980;21:469–474.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American gastroenterological association IBD parenthood project working group. Gastroenterology. 2019;156:1508–1524.
   PubMed Web of Science ®Google Scholar
• Levi AJ, Fisher A, Hughes L, et al. Male infertility due to sulphasalazine. Lancet. 1979;2:276–278.
   PubMed Web of Science ®Google Scholar
• O’Morain C, Smethurst P, Dore C, et al. Reversible male infertility due to sulphasalazine: studies in man and rat. Gut. 1984;25:1078–1084.
   PubMed Web of Science ®Google Scholar
• Matthis AL, Zhang B, Denson LA, et al. Importance of the evaluation of N-Acetyltransferase enzyme activity prior to 5-Aminosalicylic acid medication for ulcerative colitis. Inflamm Bowel Dis. 2016;22:1793–1802.
   PubMed Web of Science ®Google Scholar
• Silverman D, Ford J, Shaw I, et al. Is mesalazine really safe for use in breastfeeding mothers? Gut. 2005;54:170–171.
   PubMed Web of Science ®Google Scholar
• de Graaf P, de Boer NK, Wong DR, et al. Influence of 5-aminosalicylic acid on 6-thioguanosine phosphate metabolite levels: a prospective study in patients under steady thiopurine therapy. Br J Pharmacol. 2010;160:1083–1091.
   PubMed Web of Science ®Google Scholar
• Azad Khan A, Truelove S. Placental and mammary transfer of sulfasalazine. BMJ. 1979;2:1553.
   Google Scholar
• Jarnerot G, Into-Malmberg MB. Sulphasalazine treatment during breast feeding. Scand J Gastroenterol. 1979;14:869–871.
   PubMed Web of Science ®Google Scholar
• Branski D, Kerem E, Gross-Kieselstein E, et al. Bloody diarrhoea - a possible complication of sulfasalazine transferred through human breast milk. J Pediatr Gastr Nutr. 1986;5:316–317.
   PubMed Web of Science ®Google Scholar
• Werlin S, Grand R. Bloody diarrhoea - a new complication of sulfasalazine. J Pediatr. 1978;92:450–451.
   PubMed Web of Science ®Google Scholar
• Nelis G. Diarrhoea due to 5-aminosalicyclic acid in breast milk. Lancet. 1989;1:383.
   PubMed Web of Science ®Google Scholar
• Singh RR, Cuffe JS, Moritz KM. Short- and long-term effects of exposure to natural and synthetic glucocorticoids during development. Clin Exp Pharmacol Physiol. 2012;39:979–989.
   PubMed Web of Science ®Google Scholar
• Bandoli G, Palmsten K, Forbess Smith CJ, et al. A review of systemic corticosteroid use in pregnancy and the risk of select pregnancy and birth outcomes. Rheum Dis Clin North Am. 2017;43:489–502.
   PubMed Web of Science ®Google Scholar
• Leung YP, Kaplan GG, Coward S, et al. Intrapartum corticosteroid use significantly increases the risk of gestational diabetes in women with inflammatory bowel disease. J Crohns Colitis. 2015;9:223–230.
   PubMed Web of Science ®Google Scholar
• Lin K, Martin CF, Dassopoulos T, et al. Pregnancy outcomes amongst mothers with inflammatory bowel disease exposed to systemic corticosteroids: results of the PIANO registry. Gastroenterology. 2014;146:S1.
   Web of Science ®Google Scholar
• Truta B, Althumairi A, Canner J, et al. Potential risks of immunosuppressant drugs to the pregnant patient. Am J Gastroenterol. 2015;110:S966.
   Web of Science ®Google Scholar
• Bjorn A, Ehrenstein V, Hundborg HH, et al. Use of corticosteroids in early pregnancy is not associated with risk of oral clefts and other congenital malformations in offspring. Am J Ther. 2014;21:73–80.
   PubMed Web of Science ®Google Scholar
• Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000;62:385–392.
   PubMedGoogle Scholar
• Norgard B, Pedersen L, Christensen LA, et al. Therapeutic drug use in women with Crohn’s disease and birth outcomes: a Danish nationwide cohort study. Am J Gastroenterol. 2007;102:1406–1413.
   PubMed Web of Science ®Google Scholar
• Palmsten K, Bandoli G, Watkins J, et al. Oral corticosteroids and risk of preterm birth in the California medicaid program. J Allergy Clin Immunol Pract. 2020. Epub ahead of print. DOI:10.1016/j.jaip.2020.07.047
   PubMed Web of Science ®Google Scholar
• Homar V, Grosek S, Battelino T. High-dose methylprednisolone in a pregnant woman with Crohn’s disease and adrenal suppression in her newborn. Neonatology. 2008;94:306–309.
   PubMed Web of Science ®Google Scholar
• Edwards MJ, Agho K, Attia J, et al. Case-control study of cleft lip or palate after maternal use of topical corticosteroids during pregnancy. Am J Med Genet A. 2003;120:459–463.
   Google Scholar
• Rodriguez-Pinilla E, Martinez-Frias L. Corticosteroids during pregnancy and oral clefts: a case-control study. Teratology. 1998;58:2–5.
   PubMedGoogle Scholar
• Skuladottir H, Wilcox AJ, Ma C, et al. Corticosteroid use and risk of orofacial clefts. Birth Defects Res A Clin Mol Teratol. 2014;100:499–506.
   PubMed Web of Science ®Google Scholar
• Hviid A, Molgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ. 2011;183:796–804.
   PubMed Web of Science ®Google Scholar
• Fedorak RN, Bistritz L. Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide. Adv Drug Deliv Rev. 2005;57:303–316.
   PubMed Web of Science ®Google Scholar
• Beaulieu DB, Ananthakrishnan AN, Issa M, et al. Budesonide induction and maintenance therapy for Crohn’s disease during pregnancy. Inflamm Bowel Dis. 2009;15:25–28.
   PubMed Web of Science ®Google Scholar
• Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):590–599.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, McConnell RA, Chambers CD. Drug safety and risk of adverse outcomes for pregnant patients with inflammatory bowel disease. Gastroenterology. 2017;152:451–62 e2.
   PubMed Web of Science ®Google Scholar
• Greenberger P, Odeh Y, Frederiksen M, et al. Pharmacokinetics of prednisolone transfer to breast milk. Clin Pharm Ther. 1993;53(3):324–328.
   PubMed Web of Science ®Google Scholar
• Ost L, Wettrell G, Bjorkhem I, et al., Prednisolone excretion in human milk. J Pediatr. 106(6): 1008–1011. 1985.
   PubMed Web of Science ®Google Scholar
• Ryu RJ, Easterling TR, Caritis SN, et al. Prednisone pharmacokinetics during pregnancy and lactation. J Clin Pharmacol. 2018;58(9):1223–1232.
   PubMed Web of Science ®Google Scholar
• Falt A, Bengtsson T, Kennedy BM, et al. Exposure of infants to budesonide through breast milk of asthmatic mothers. J Allergy Clin Immunol. 2007;120:798–802.
   PubMed Web of Science ®Google Scholar
• Middleton PG, Gade EJ, Aguilera C, et al. ERS/TSANZ task force statement on the management of reproduction and pregnancy in women with airways diseases. Eur Respir J. 2020;55:1901208.
   PubMed Web of Science ®Google Scholar
• Lactmed: drugs and lactation database. Hydrocortisone 2020 [updated 2020 Jun 15]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK500976/
   Google Scholar
• Izumi Y, Miyashita T, Migita K. Safety of tacrolimus treatment during pregnancy and lactation in systemic lupus erythematosus: a report of two patients. Tohoku J Exp Med. 2014;234(1):51–56.
   PubMed Web of Science ®Google Scholar
• Nyberg G, Haljamae U, Frisenette-Fich C, et al. Breast-feeding during treatment with cyclosporine. Transplantation. 1998;65:253–255.
   PubMed Web of Science ®Google Scholar
• Polifka JE, Friedman JM. Teratogen update: azathioprine and 6-mercaptopurine. Teratology. 2002;65(5):240–261.
   PubMedGoogle Scholar
• Saarikoski S, Seppala M. Immunosuppression during pregnancy: transmission of azathioprine and its metabolites from the mother to the fetus. Am J Obstet Gynecol. 1973;115(8):1100–1106.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology. 2006;131(1):283–311.
   PubMed Web of Science ®Google Scholar
• de Boer NK, Jarbandhan SV, de Graaf P, et al. Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites. Am J Gastroenterol. 2006;101:1390–1392.
   PubMed Web of Science ®Google Scholar
• Jharap B, de Boer NK, Stokkers P, et al. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease. Gut. 2014;63:451–457.
   PubMed Web of Science ®Google Scholar
• Coelho J, Beaugerie L, Colombel JF, et al. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut. 2011;60:198–203.
   PubMed Web of Science ®Google Scholar
• Kanis SL, de Lima-karagiannis A, de Boer NKH, et al. Use of Thiopurines during conception and pregnancy is not associated with adverse pregnancy outcomes or health of infants at one year in a prospective study. Clin Gastroenterol Hepatol. 2017;15:1232–41 e1.
   PubMed Web of Science ®Google Scholar
• Cleary B, Kallen B. Early pregancny azathioprine use and pregnancy outcomes. Birth Defects Res A Clin Mol Teratol. 2009;85:647–654.
   PubMed Web of Science ®Google Scholar
• Cote C, Meuwissen H, Pickering R. Effects on the neonate of prednisone and azathioprine administered to the mother during pregnancy. J Pediatr. 1974;85:324–328.
   PubMed Web of Science ®Google Scholar
• Williamson R, Karp L. Azathioprine teratogenicity: review of the literature and case report. Obstet Gynecol. 1981;58:247–250.
   PubMed Web of Science ®Google Scholar
• Akbari M, Shah S, Velayos FS, et al. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:15–22.
   PubMed Web of Science ®Google Scholar
• Casanova MJ, Chaparro M, Domenech E, et al. Safety of thiopurines and anti-TNF-alpha drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol. 2013;108:433–440.
   PubMed Web of Science ®Google Scholar
• Francella A, Dyan A, Bodian C, et al. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology. 2003;124:9–17.
   PubMed Web of Science ®Google Scholar
• Hutson JR, Matlow JN, Moretti ME, et al. The fetal safety of thiopurines for the treatment of inflammatory bowel disease in pregnancy. J Obstet Gynaecol. 2013;33:1–8.
   PubMedGoogle Scholar
• Langagergaard V, Pedersen L, Gislum M, et al. Birth outcome in women treated with azathioprine or mercaptopurine during pregnancy: a Danish nationwide cohort study. Aliment Pharmacol Ther. 2007;25:73–81.
   PubMed Web of Science ®Google Scholar
• Mozaffari S, Abdolghaffari AH, Nikfar S, et al. Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: a systematic review with meta-analysis. Hum Exp Toxicol. 2015;34:445–459.
   PubMed Web of Science ®Google Scholar
• Angelberger S, Reinisch W, Messerschmidt A, et al. Long-term follow-up of babies exposed to azathioprine in utero and via breastfeeding. J Crohns Colitis. 2011;5:95–100.
   PubMed Web of Science ®Google Scholar
• de Meij TG, Jharap B, Kneepkens CM, et al. Long-term follow-up of children exposed intrauterine to maternal thiopurine therapy during pregnancy in females with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38:38–43.
   PubMed Web of Science ®Google Scholar
• Koslowsky B, Sadeh C, Grisaru-Granovsky S, et al. Thiopurine therapy for inflammatory bowel disease during pregnancy is not associated with anemia in the infant. Dig Dis Sci. 2019;64(8):2286–2290.
   PubMed Web of Science ®Google Scholar
• de Boer NK, Van Elburg RM, Wilhelm AJ, et al. 6-Thioguanine for Crohn’s disease during pregnancy: thiopurine metabolite measurements in both mother and child. Scand J Gastroenterol. 2005;40:1374–1377.
   PubMed Web of Science ®Google Scholar
• van den Berg SA, de Boer M, van der Meulen-de Jong AE, et al., Safety of tioguanine during pregnancy in inflammatory bowel disease. J Crohns Colitis. 10(2): 159–165. 2016.
   PubMed Web of Science ®Google Scholar
• Pavlidis P, Ansari A, Duley J, et al. Splitting a therapeutic dose of thioguanine may avoid liver toxicity and be an efficacious treatment for severe inflammatory bowel disease: a 2-center observational cohort study. Inflamm Bowel Dis. 2014;20(12):2239–2246.
   PubMed Web of Science ®Google Scholar
• Christensen LA, Dahlerup JF, Nielsen MJ, et al. Azathioprine treatment during lactation. Aliment Pharmacol Ther. 2008;28:1209–1213.
   PubMed Web of Science ®Google Scholar
• Gardiner SJ, Gearry RB, Roberts RL, et al. Exposure to thiopurine drugs through breast milk is low based on metabolite concentrations in mother-infant pairs. Br J Clin Pharmacol. 2006;62:453–456.
   PubMed Web of Science ®Google Scholar
• Moretti ME, Verjee Z, Ito S, et al. Breast-feeding during maternal use of azathioprine. Ann Pharmacother. 2006;40:2269–2272.
   PubMed Web of Science ®Google Scholar
• Sau A, Clarke S, Bass J, et al. Azathioprine and breastfeeding: is it safe? BJOG. 2007;114:498–501.
   PubMed Web of Science ®Google Scholar
• Seinen ML, de Boer NK, van Hoorn ME, et al. Safe use of allopurinol and low-dose mercaptopurine therapy during pregnancy in an ulcerative colitis patient. Inflamm Bowel Dis. 2013;19:E37.
   PubMed Web of Science ®Google Scholar
• Simsek M, Opperman RCM, Mulder CJJ, et al. The teratogenicity of allopurinol: a comprehensive review of animal and human studies. Reprod Toxicol. 2018;81:180–187.
   PubMed Web of Science ®Google Scholar
• Fujii T, Nishimura H. Comparison of teratogenic action of substances related to purine metabolism in mouse embryos. Jap J Pharmacol. 1972;22:201–206.
   PubMedGoogle Scholar
• Hoeltzenbein M, Stieler K, Panse M, et al. Allopurinol use during pregnancy - outcome of 31 prospectively ascertained cases and a phenotype possibly indicative for teratogenicity. PLoS One. 2013;8:e66637.
   PubMed Web of Science ®Google Scholar
• Kozenko M, Grynspan D, Oluyomi-Obi T, et al. Potential teratogenic effects of allopurinol: a case report. Am J Med Genet A. 2011;155:2247–2252.
   Google Scholar
• Fazal M, Doogue M, Leong RW, et al. Allopurinol use in pregnancy in three women with inflammatory bowel disease: safety and outcomes: a case series. BMC Gastroenterol. 2013;13:1–5.
   PubMed Web of Science ®Google Scholar
• Sheikh M, Nelson-Piercy C, Duley J, et al. Successful Pregnancies with Thiopurine-Allopurinol Co-Therapy for Inflammatory Bowel Disease. J Crohns Colitis. 2015;9:680–684.
   PubMed Web of Science ®Google Scholar
• Beswick L, Shukla D, Friedman A, et al. National audit: assessing the use and safety of allopurinol thiopurine co-therapy in pregnant females with inflammatory bowel disease. J Gastroenterol Hepatol. 2016;31:128–129.
   Web of Science ®Google Scholar
• Elion G. Enzymatic and metabolic studies with allopurinol. Ann Rheum Dis. 1966;25:608–614.
   PubMed Web of Science ®Google Scholar
• Pea F. Pharmacology of drugs for hyperuricemia: mechanisms, kinetics and interactions. Contrib Nephrol. 2005;147:35–46.
   PubMed Web of Science ®Google Scholar
• Kamilli I, Gresser U. Allopurinol and oxypurinol in human breast milk. Clin Investig. 1993;71:161–164.
   PubMedGoogle Scholar
• Lloyd M, Carr M, McElhatton P, et al. The effects of methotrexate on pregnancy, fertility and lactation. Q J Med. 1999;92:551–563.
   Google Scholar
• Nielsen OH, Steenholdt C, Juhl CB, et al. Efficacy and safety of methotrexate in the management of inflammatory bowel disease: A systematic review and meta-analysis of randomized, controlled trials. EClinicalMedicine. 2020;20:100271.
   PubMedGoogle Scholar
• Woolf RT, West SL, Arenas-Hernandez M, et al. Methotrexate polyglutamates as a marker of patient compliance and clinical response in psoriasis: a single-centre prospective study. Br J Dermatol. 2012;167:165–173.
   PubMed Web of Science ®Google Scholar
• Dalrymple JM, Stamp LK, O’Donnell JL, et al. Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2008;58:3299–3308.
   PubMed Web of Science ®Google Scholar
• Bermas B, Hill J. Effects of immunosuppressive drugs during pregnancy. Arthritis Rheum. 1995;38:1722–1732.
   PubMed Web of Science ®Google Scholar
• Ley D, Jones J, Parrish J, et al. Methotrexate reduces DNA integrity in sperm from men with inflammatory bowel disease. Gastroenterology. 2018;154:2064–7 e3.
   PubMed Web of Science ®Google Scholar
• Weber-Schoendorfer C, Chambers C, Wacker E, et al. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis Rheumatol. 2014;66:1101–1110.
   PubMed Web of Science ®Google Scholar
• Sussman A, Leonard J. Psoriasis, methotrexate and oligospermia. Arch Dermatol. 1980;116:215–217.
   PubMed Web of Science ®Google Scholar
• Shamberger R, Rosenberg S, Seipp C, et al. Effects of high dose methotrexate and vincristine on ovarian and testicular function in patients undergoing post-operative adjuvant treatment of osteosarcoma. Cancer Treat Rep. 1981;65:739–746.
   PubMedGoogle Scholar
• Grosen A, Kelsen J, Hvas CL, et al. The influence of methotrexate treatment on male fertility and pregnancy outcome after paternal exposure. Inflamm Bowel Dis. 2017;23:561–569.
   PubMed Web of Science ®Google Scholar
• Blackburn W, Alarcon G. Impotence in three rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum. 1989;32:1341–1342.
   PubMedGoogle Scholar
• Shim HH, Seow CH. Editorial: vedolizumab in pregnancy - is gut selectivity as good for baby as it is for mum? Aliment Pharmacol Ther. 2017;45:1283–1284.
   PubMed Web of Science ®Google Scholar
• Delaney S, Colantonio D, Ito S. Methotrexate in breast milk. Birth Defects Res. 2017;109:711.
   Google Scholar
• Thorne JC, Nadarajah T, Moretti M, et al. Methotrexate use in a breastfeeding patient with rheumatoid arthritis. J Rheumatol. 2014;41:2332.
   PubMedGoogle Scholar
• Johns DG, Rutherford LD, Leighton PC, et al. Secretion of methotrexate into human milk. Am J Obstet Gynecol. 1972;112:978–980.
   PubMed Web of Science ®Google Scholar
• Australian Rheumatology Association. Notes on prescribing medications for rheumatic diseases in pregnancy. 2017 cited 2020 Jun 14:[13 p.]. Available from: https://rheumatology.org.au/gps/documents/ARAPregnancyPrescribingnotes151018final__000.pdf.
   Google Scholar
• Gotestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75:795–810.
   PubMed Web of Science ®Google Scholar
• van der Woude CJ, Ardizzone S, Bengtson MB, et al. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis. 2015;9:107–124.
   PubMed Web of Science ®Google Scholar
• Stein R, Hanauer S. Comparative tolerability of treatments for Inflammatory Bowel Disease. Drug Saf. 2000;23(5):429–448.
   PubMed Web of Science ®Google Scholar
• Petri M. Immunosuppressive drug use in pregnancy. Autoimmunity. 2003;36(1):51–56.
   PubMed Web of Science ®Google Scholar
• Bertschinger P, Himmelmann A, Risti B, et al. Cyclosporine treatment of severe ulcerative colitis during pregnancy. Am J Gastroenterol. 1995;90:330.
   PubMed Web of Science ®Google Scholar
• Branche J, Cortot A, Bourreille A, et al. Cyclosporine treatment for steroid-refractory ulcerative colitis during pregnancy. Inflamm Bowel Dis. 2009;15:1044–1048.
   PubMed Web of Science ®Google Scholar
• Lahiff C, Moss A. Cyclosporine in the management of severe ulcerative colitis while breast-feeding. Inflamm Bowel Dis. 2011;17(7):E78.
   PubMedGoogle Scholar
• Reindl W, Schmid R, Huber W. Cyclosporin A treatment of steroid- refractory ulcerative colitis during pregnancy: report of two cases. Gut. 2007;56:1019–1036.
   PubMed Web of Science ®Google Scholar
• Oz B B, Hackman R, Einarson T, et al. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation. 2001;71:1051–1055.
   PubMed Web of Science ®Google Scholar
• Paziana K, Del Monaco M, Cardonick E, et al. Ciclosporin use during pregnancy. Drug Saf. 2013;36(5):279–294.
   PubMed Web of Science ®Google Scholar
• Bae YS, Van Voorhees AS, Hsu S, et al. Review of treatment options for psoriasis in pregnant or lactating women: from the medical board of the national psoriasis foundation. J Am Acad Dermatol. 2012;67:459–477.
   PubMed Web of Science ®Google Scholar
• Moretti ME, Sgro M, Johnson DW, et al. Cyclosporine excretion into breast milk. Transplantation. 2003;75(12):2144–2146.
   PubMed Web of Science ®Google Scholar
• Morton A. Cyclosporine and lactation. Nephrology. 2011;16:249–250.
   PubMed Web of Science ®Google Scholar
• Czeizel A, Rockenbauer M. A population based case-control teratologic study of oral metronidazole treatment during pregnancy. BJOG. 1998;105:322–327.
   Google Scholar
• Shennan A, Crawshaw S, Briley A, et al. A randomised controlled trial of metronidazole for the prevention of preterm birth in women positive for cervicovaginal fetal fibronectin: the PREMET Study. BJOG. 2006;113:65–74.
   PubMed Web of Science ®Google Scholar
• Burtin P, Taddio A, Ariburnu O, et al. Safety of metronidazole in pregnancy: a meta-analysis. Am J Obstet Gynecol. 1995;172(2):525–529.
   PubMed Web of Science ®Google Scholar
• Caro-Paton T, Carvajal A, de Diego I, et al. Is metronidazole teratogenic? A meta-analysis. Br J Clin Pharmacol. 1987;44:179–182.
   Google Scholar
• Koss CA, Baras DC, Lane SD, et al. Investigation of metronidazole use during pregnancy and adverse birth outcomes. Antimicrob Agents Chemother. 2012;56(9):4800–4805.
   PubMed Web of Science ®Google Scholar
• Passmore C, McElnay J, Rainey E, et al. Metronidazole excretion in human milk and its effect on the suckling neonate. Br J Clin Pharmacol. 1988;26:45–51.
   PubMed Web of Science ®Google Scholar
• Gray M, Squires K. Further observations on metronidazole (Flagyl). Brit J Vener Dis. 1961;37:278–279.
   PubMedGoogle Scholar
• Bar-Oz B, Moretti ME, Boskovic R, et al. The safety of quinolones–a meta-analysis of pregnancy outcomes. Eur J Obstet Gynecol Reprod Biol. 2009;143:75–78.
   PubMed Web of Science ®Google Scholar
• Larsen H, Nielsen G, Schonheyder HC, et al. Birth outcome following maternal use of fluoroquinolones. Int J Antimicrob Agents. 2001;18:259–262.
   PubMed Web of Science ®Google Scholar
• Moskovitz DN, Bodian C, Chapman ML, et al. The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am J Gastroenterol. 2004;99(4):656–661.
   PubMed Web of Science ®Google Scholar
• Wogelius P, Norgaard M, Gislum M, et al. Further analysis of the risk of adverse birth outcome after maternal use of fluoroquinolones. Int J Antimicrob Agents. 2005;26(4):323–326.
   PubMed Web of Science ®Google Scholar
• Ziv A, Masarwa R, Perlman A, et al. Pregnancy outcomes following exposure to quinolone antibiotics - a systematic-review and meta-analysis. Pharm Res. 2018;35:109.
   PubMed Web of Science ®Google Scholar
• Giamarellou H, Kolokythas E, Petrikkos G, et al. Pharmacokinetics of three newer quinolones in pregnant and lactating women. Am J Med. 1989;87:49–51S.
   PubMed Web of Science ®Google Scholar
• Burkhardt J, Hill M, Carlton W, et al. Histologic and histochemical changes in articular cartilages of immature beagle dogs dosed with difloxacin, a fluoroquinolone. Vet Pathol. 1990;27(3):162–170.
   PubMed Web of Science ®Google Scholar
• Linseman D, Hampton L, Branstetter D. Quinolone-induced arthropathy in the neonatal mouse: morphological analysis of articular lesions produced by pipemidic acid and ciprofloxacin. Fundam Appl Toxicol. 1995;28:59–64.
   PubMedGoogle Scholar
• Harmon T, Burkhart G, Applebaum H. Perforated pseudomembranous colitis in the breast-fed infant. J Pediatr Surg. 1992;27:744–746.
   PubMed Web of Science ®Google Scholar
• LactMed: drugs and lactation database. Ciprofloxacin 2018. [cited 2020 Dec 23]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK501583/
   Google Scholar
• Damman JL, Rodriguez EA, Ali AH, et al. Review article: the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis. Aliment Pharmacol Ther. 2018;47(7):886–895.
   PubMed Web of Science ®Google Scholar
• Onwuchuruba CN, Towers CV, Howard BC, et al. Transplacental passage of vancomycin from mother to neonate. Am J Obstet Gynecol. 2014;210(352):e1- e4.
   PubMedGoogle Scholar
• Towers CV, Weitz B. Transplacental passage of vancomycin. J Matern Fetal Neonatal Med. 2018;31:1021–1024.
   PubMed Web of Science ®Google Scholar
• Reyes M, O’strea E, Cabinian A, et al. Vancomycin during pregnancy: does it cause hearing loss or nephrotoxicity in the infant? Am J Obstet Gynecol. 1989;161:187.
   Web of Science ®Google Scholar
• Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1–s106.
   PubMed Web of Science ®Google Scholar
• Adachi J, DuPont H. Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. Expert Rev Anti Infect Ther. 2006;42:541–547.
   Google Scholar
• Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy. 2005;51(Suppl 1):36–66.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Supplement Approval: reference ID: 2863655. 2010. [cited 2020 Dec 23]. Available from https://wwwaccessdatafdagov/drugsatfda_docs/appletter/2010/021361s009ltrpdf
   Google Scholar
• Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R, et al. Tumor necrosis factor-alpha and pregnancy: focus on biologics. An updated and comprehensive review. Clin Rev Allergy Immunol. 2017;53:40–53.
   PubMed Web of Science ®Google Scholar
• Flanagan E, Gibson PR, Wright EK, et al. Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure. Aliment Pharmacol Ther. 2020;52:1551–1562.
   PubMed Web of Science ®Google Scholar
• Zelinkova Z, de Haar C, de Ridder L, et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther. 2011;33:1053–1058.
   PubMed Web of Science ®Google Scholar
• Malek A, Sager R, Kuhn P, et al. Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am J Reproduct Immunol. 1996;36:248–255.
   PubMed Web of Science ®Google Scholar
• de Lima A, Zelinkova Z, van der Ent C, et al. Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety. Gut. 2016;65:1261–1268.
   PubMed Web of Science ®Google Scholar
• Zelinkova Z, van der Ent C, Bruin KF, et al. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Clin Gastroenterol Hepatol. 2013;11:318–321.
   PubMed Web of Science ®Google Scholar
• Julsgaard M, Christensen LA, Gibson PR, et al. Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection. Gastroenterology. 2016;151:110–119.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:286–292.
   PubMed Web of Science ®Google Scholar
• Kanis SL, de Lima-karagiannis A, van der Ent C, et al. Anti-TNF levels in cord blood at birth are associated with Anti-TNF Type. J Crohns Colitis. 2018;12(8):939–947.
   PubMed Web of Science ®Google Scholar
• Kanis SL, de Lima A, Van Der Woude CJ. Optimal Anti-TNF stop week during pregnancy depends on Anti-TNF Type. Gastroenterology. 2017;152(5):S11.
   Web of Science ®Google Scholar
• Marchioni RM, Lichtenstein GR. Tumor necrosis factor-alpha inhibitor therapy and fetal risk: a systematic literature review. World J Gastroenterol. 2013;19:2591–2602.
   PubMed Web of Science ®Google Scholar
• Deepak P, Stobaugh DJ. Maternal and foetal adverse events with tumour necrosis factor-alpha inhibitors in inflammatory bowel disease. Aliment Pharmacol Ther. 2014;40(9):1035–1043.
   PubMed Web of Science ®Google Scholar
• Diav-Citrin O, Otcheretianski-Volodarsky A, Shechtman S, et al. Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observational study. Reprod Toxicol. 2014;43:78–84.
   PubMed Web of Science ®Google Scholar
• Kiely CJ, Subramaniam K, Platten J, et al. Safe and effective: anti-tumour necrosis factor therapy use in pregnant patients with Crohn disease and ulcerative colitis. Intern Med J. 2016;46:616–619.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Mahadevan U, et al. Pregnancy outcomes reported during the 13-Year TREAT registry: a descriptive report. Am J Gastroenterol. 2018;113(11):1678–1688.
   PubMed Web of Science ®Google Scholar
• Narula N, Al-Dabbagh R, Dhillon A, et al. Anti-TNFalpha therapies are safe during pregnancy in women with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2014;20:1862–1869.
   PubMed Web of Science ®Google Scholar
• Seirafi M, de Vroey B, Amiot A, et al. Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease. Aliment Pharmacol Ther. 2014;40:363–373.
   PubMed Web of Science ®Google Scholar
• Nielsen OH, Gubatan JM, Juhl CB, et al. Biologics for inflammatory bowel disease and their safety in pregnancy: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2020. DOI:10.1016/j.cgh.2020.09.021. Epub ahead of print.
   Google Scholar
• Luu M, Benzenine E, Doret M, et al. Continuous Anti-TNFalpha use throughout pregnancy: possible complications for the mother but not for the fetus. a retrospective cohort on the french national health insurance database (EVASION). Am J Gastroenterol. 2018;113:1669–1677.
   PubMed Web of Science ®Google Scholar
• Chaparro M, Verreth A, Lobaton T, et al. Long-term safety of in utero exposure to Anti-TNFalpha drugs for the treatment of inflammatory bowel disease: results from the multicenter European TEDDY Study. Am J Gastroenterol. 2018;113:396–403.
   PubMed Web of Science ®Google Scholar
• Broms G, Kieler H, Ekbom A, et al. Anti-TNF treatment during pregnancy and birth outcomes: a population-based study from Denmark, Finland, and Sweden. Pharmacoepidemiol Drug Saf. 2020;29:316–327.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Vermeire S, Lasch K, et al. Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45:941–950.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Chaparro M. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am J Gastroenterol. 2013;108:1426–1438.
   PubMed Web of Science ®Google Scholar
• Steenholdt C, Al-Khalaf M, Ainsworth MA, et al. Therapeutic infliximab drug level in a child born to a woman with ulcerative colitis treated until gestation week 31. J Crohns Colitis. 2012;6:358–361.
   PubMed Web of Science ®Google Scholar
• Labetoulle R, Roblin X, Paul S. Prolonged persistence of adalimumab transferred from mother to infant during pregnancy. Ann Intern Med. 2018;169:60–61.
   PubMed Web of Science ®Google Scholar
• Nielsen OH, Loftus E, Jess T. Safety of TNF-α inhibitors during IBD pregnancy: a systematic review. BMC Med. 2013;11:174.
   PubMed Web of Science ®Google Scholar
• Duricova D, Dvorakova E, Hradsky O, et al. Safety of Anti-TNF-Alpha therapy during pregnancy on long-term outcome of exposed children: a controlled, multicenter observation. Inflamm Bowel Dis. 2019;25:789–796.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Long MD, Kane SV, et al. Pregnancy and Neonatal Outcomes after Fetal Exposure To Biologics and Thiopurines among Women with Inflammatory Bowel Disease. Gastroenterology. Epub ahead of print. 2020. DOI:10.1053/j.gastro.2020.11.038
   Web of Science ®Google Scholar
• Gubatan J, Nielsen OH, Levitte S, et al. Biologics during pregnancy in women with inflammatory bowel disease and risk of infantile infections: a systematic review and meta-analysis. Am J Gastroenterol. 2020. DOI:10.14309/ajg.0000000000000910.
   PubMedGoogle Scholar
• Guiddir T, Fremond ML, Triki TB, et al. Anti-TNF-alpha therapy may cause neonatal neutropenia. Pediatrics. 2014;134:e1189–93.
   PubMed Web of Science ®Google Scholar
• Kattah MG, Milush JM, Burt T, et al. Anti-TNF and thiopurine therapy in pregnant IBD patients does not significantly alter a panel of B-cell and T-cell subsets in 1-year-old infants. Clin Transl Gastroenterol. 2018;9:143.
   PubMed Web of Science ®Google Scholar
• Cheent K, Nolan J, Shariq S, et al. Case Report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn’s disease. J Crohns Colitis. 2010;4:603–605.
   PubMed Web of Science ®Google Scholar
• Park SH, Kim HJ, Lee CK, et al. Safety and optimal timing of BCG vaccination in infants born to mothers receiving anti-TNF therapy for inflammatory bowel disease. J Crohns Colitis. 2020;14(12):1780–1784. Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Bortlik M, Duricova D, Machkova N, et al. Impact of anti-tumor necrosis factor alpha antibodies administered to pregnant women with inflammatory bowel disease on long-term outcome of exposed children. Inflamm Bowel Dis. 2014;20:495–501.
   PubMed Web of Science ®Google Scholar
• Truta B, Canner J, Fang S, et al. Early discontinuation of adalimumab therapy in IBD pregnancy. Gastroenterol. 2020;158:S453.
   Web of Science ®Google Scholar
• Schnitzler F, Fidder H, Ferrante M, et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis. 2011;17:1846–1854.
   PubMed Web of Science ®Google Scholar
• Truta B, Leeds IL, Canner JK, et al. Early discontinuation of infliximab in pregnant women with inflammatory bowel disease. Inflamm Bowel Dis. 2020;26:1110–1117.
   PubMed Web of Science ®Google Scholar
• Fernekorn U, Butcher EC, Behrends J, et al. Functional involvement of P-selectin and MAdCAM-1 in the recruitment of alpha4beta7-integrin-expressing monocyte-like cells to the pregnant mouse uterus. Eur J Immunol. 2004;34:3423–3433.
   PubMed Web of Science ®Google Scholar
• Zelinkova Z, Berakova K, Podmanicky D, et al. Placental MadCAM1 expression and potential consequences for the treatment with Vedolizumab during pregnancy. Gastroenterology. 2017;152:S764–S5.
   Web of Science ®Google Scholar
• Rosario M, Dirks NL, Gastonguay MR, et al. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn’s disease. Aliment Pharmacol Ther. 2015;42:188–202.
   PubMed Web of Science ®Google Scholar
• Crawford D, Friedman M. Safety analysis of vedolizumab during pregnancy: findings from a reproductive study in monkeys. Gastroenterol. 2018;154:S129.
   Web of Science ®Google Scholar
• Food and drug administration. Entyvio prescribing information. 2014. [cited 2020 July 24]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125476s000lbl.pdf.
   Google Scholar
• Moens A, van der Woude CJ, Julsgaard M, et al. Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. Aliment Pharmacol Ther. 2020;51:129–138.
   PubMed Web of Science ®Google Scholar
• Bar-Gil Shitrit A, Ben Ya’acov A, Livovsky DM, et al. Exposure to Vedolizumab in IBD pregnant women appears of low risk for mother and neonate: a first prospective comparison study. Am J Gastroenterol. 2019;114:1172–1175.
   PubMed Web of Science ®Google Scholar
• Julsgaard M, Kjeldsen J, Baumgart DC. Vedolizumab safety in pregnancy and newborn outcomes. Gut. 2017;66:1866–1867.
   PubMed Web of Science ®Google Scholar
• Sheridan J, Cullen G, Doherty G. Letter: vedolizumab in pregnancy. J Crohns Colitis. 2017;11:1025–1026.
   PubMed Web of Science ®Google Scholar
• Moens A, van Hoeve K, Humblet E, et al. Outcome of pregnancies in female patients with inflammatory bowel diseases treated with Vedolizumab. J Crohns Colitis. 2019;13:12–18.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Martin C, Kane SV, et al. Do infant serum levels of biologic agents at birth correlate with risk of adverse outcomes? Results From the PIANO registry. Gastroenterology. 2016;150:S91–2.
   Web of Science ®Google Scholar
• Pipek B, Duricova D, Mitrova K, et al. Vedolizumab drug levels in maternal cord blood following treatment of inflammatory bowel disease in pregnancy: ongoing multicentre prospective study from the Czech Republic. Gastroenterol. 2020;158:S451.
   Web of Science ®Google Scholar
• Flanagan E, Gibson PR, Begun J, et al. Letter: vedolizumab drug concentrations in neonates following intrauterine exposure. Aliment Pharmacol Ther. 2018;48(11–12):1328–1330.
   PubMed Web of Science ®Google Scholar
• Scott FI, Osterman MT. Natalizumab for crohn’s disease: down but not out. Clin Gastroenterol Hepatol. 2015;13(11):1926–1928.
   PubMed Web of Science ®Google Scholar
• Selewski DT, Shah GV, Segal BM, et al. Natalizumab (Tysabri). AJNR Am J Neuroradiol. 2010;31(9):1588–1590.
   PubMed Web of Science ®Google Scholar
• Proschmann U, Thomas K, Thiel S, et al. Natalizumab during pregnancy and lactation. Mult Scler. 2018;24(12):1627–1634.
   PubMed Web of Science ®Google Scholar
• Wehner NG, Shopp G, Oneda S, et al. Embryo/fetal development in cynomolgus monkeys exposed to natalizumab, an alpha4 integrin inhibitor. Birth Defects Res B Dev Reprod Toxicol. 2009;86:117–130.
   PubMed Web of Science ®Google Scholar
• Haghikia A, Langer-Gould A, Rellensmann G, et al. Natalizumab use during the third trimester of pregnancy. JAMA Neurol. 2014;71:891–895.
   PubMed Web of Science ®Google Scholar
• Triplett JD, Vijayan S, Rajanayagam S, et al. Pregnancy outcomes amongst multiple sclerosis females with third trimester natalizumab use. Mult Scler Relat Disord. 2020;40:101961.
   PubMed Web of Science ®Google Scholar
• Friend S, Richman S, Bloomgren G, et al. Evaluation of pregnancy outcomes from the Tysabri(R) (natalizumab) pregnancy exposure registry: a global, observational, follow-up study. BMC Neurol. 2016;16:150.
   PubMed Web of Science ®Google Scholar
• Ebrahimi N, Herbstritt S, Gold R, et al. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study. Mult Scler. 2015;21:198–205.
   PubMed Web of Science ®Google Scholar
• Benson JM, Peritt D, Scallon BJ, et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs. 2011;3:535–545.
   PubMed Web of Science ®Google Scholar
• Ledee-Bataille N, Dubanchet S, Coulomb-L’hermine A, et al. A new role for natural killer cells, interleukin (IL)-12, and IL-18 in repeated implantation failure after in vitro fertilization. Fertil Steril. 2004;81:59–65.
   PubMed Web of Science ®Google Scholar
• Wieringa JW, Driessen GJ, Van Der Woude CJ. Pregnant women with inflammatory bowel disease: the effects of biologicals on pregnancy, outcome of infants, and the developing immune system. Expert Rev Gastroenterol Hepatol. 2018;12(8):811–818.
   PubMed Web of Science ®Google Scholar
• Cai J, Li M, Huang Q, et al. Differences in Cytokine Expression and STAT3 Activation between Healthy Controls and Patients of Unexplained Recurrent Spontaneous Abortion (URSA) during Early Pregnancy. PLoS One. 2016;11:e0163252.
   PubMed Web of Science ®Google Scholar
• Klenske E, Osaba L, Nagore D, et al. Drug levels in the maternal serum, cord blood and breast milk of a Ustekinumab-Treated patient with crohn’s disease. J Crohns Colitis. 2019;13:267–269.
   PubMed Web of Science ®Google Scholar
• Rowan CR, Cullen G, Mulcahy HE, et al. Ustekinumab drug levels in maternal and cord blood in a woman with crohn’s disease treated until 33 weeks of gestation. J Crohns Colitis. 2018;12:376–378.
   PubMed Web of Science ®Google Scholar
• Martin PL, Sachs C, Imai N, et al. Development in the cynomolgus macaque following administration of ustekinumab, a human anti-IL-12/23p40 monoclonal antibody, during pregnancy and lactation. Birth Defects Res B Dev Reprod Toxicol. 2010;89:351–363.
   PubMed Web of Science ®Google Scholar
• Cortes X, Borras-Blasco J, Antequera B, et al. Ustekinumab therapy for Crohn’s disease during pregnancy: a case report and review of the literature. J Clin Pharm Ther. 2017;42:234–236.
   PubMed Web of Science ®Google Scholar
• Venturin C, Nancey S, Danion P, et al. Fetal death in utero and miscarriage in a patient with Crohn’s disease under therapy with ustekinumab: case-report and review of the literature. BMC Gastroenterol. 2017;17(1):80.
   PubMedGoogle Scholar
• Galli-Novak E, Mook SC, Buning J, et al. Successful pregnancy outcome under prolonged ustekinumab treatment in a patient with Crohn’s disease and paradoxical psoriasis. J Eur Acad Dermatol Venereol. 2016;30:e191–2.
   PubMed Web of Science ®Google Scholar
• Scherl E, Jacobstein D, Murphy C, et al. Pregnancy outcomes in women exposed to ustekinumab in the Crohn’s disease clinical development program. J Am Acad Dermatol. 2014;70:166.
   Web of Science ®Google Scholar
• Geldhof A, Volger S, Lin CB, et al. Pregnancy outcomes in women with psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis treated with ustekinumab. J Crohns Colitis. 2020;14:S460.
   Web of Science ®Google Scholar
• Rugonyi S. Genetic and flow anomalies in congenital heart disease. AIMS Genet. 2016;3:157–166.
   PubMed Web of Science ®Google Scholar
• Lahat A, Shitrit AB, Naftali T, et al. Vedolizumab levels in breast milk of nursing mothers with inflammatory bowel disease. J Crohns Colitis. 2018;12:120–123.
   PubMedGoogle Scholar
• Ben-Horin S, Yavzori M, Kopylov U, et al. Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. J Crohns Colitis. 2011;5(6):555–558.
   PubMed Web of Science ®Google Scholar
• Julsgaard M, Kjeldsen J, Bibby BM, et al. Vedolizumab concentrations in the breast milk of nursing mothers with inflammatory bowel disease. Gastroenterology. 2018;154:752–4 e1.
   PubMed Web of Science ®Google Scholar
• Lim J, Hammami MB, Mahadevan U. Infliximab use in a child with ulcerative colitis and prior in utero exposure to infliximab. Gastroenterology. 2020;158(6):1834–1835.
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Yavzori M, Katz L, et al. Adalimumab level in breast milk of a nursing mother. Clin Gastroenterol Hepatol. 2010;8:475–476.
   PubMed Web of Science ®Google Scholar
• Fritzsche J, Pilch A, Mury D, et al. Infliximab and adalimumab use during breastfeeding. J Clin Gastroenterol. 2012;46(8):718–719.
   PubMed Web of Science ®Google Scholar
• Sun W, Fennimore B, Beaulieu D, et al. Vedolizumab levels in breast milk: results from a prospective, postmarketing, milk-only lactation study in nursing mothers with inflammatory bowel disease. J Crohns Colitis. 2020;14:S442.
   Web of Science ®Google Scholar
• Ciplea AI, Langer-Gould A, de Vries A, et al. Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2020;7:1–8.
   Web of Science ®Google Scholar
• Pfizer Inc. Xeljanz prescribing information. 2014. [cited 2020 Aug 17]. Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=959
   Google Scholar
• Mahadevan U, Dubinsky MC, Su C, et al. Outcomes of pregnancies with maternal/paternal exposure in the tofacitinib safety databases for ulcerative colitis. Inflamm Bowel Dis. 2018;24(12):2494–2500.
   PubMed Web of Science ®Google Scholar
• Clowse ME, Feldman SR, Isaacs JD, et al. Pregnancy outcomes in the tofacitinib safety databases for rheumatoid arthritis and psoriasis. Drug Saf. 2016;39:755–762.
   PubMed Web of Science ®Google Scholar
• Forger F, Villiger PM. Treatment of rheumatoid arthritis during pregnancy: present and future. Expert Rev Clin Immunol. 2016;12(9):937–944.
   PubMed Web of Science ®Google Scholar